Quantcast

Latest Gut flora Stories

2014-09-17 12:27:55

Rebiotix microbiota-based drug candidate used to assess a non-antibiotic approach to an urgent public health threat ROSEVILLE, Minn., Sept. 17, 2014 /PRNewswire/ -- Rebiotix Inc. announced this morning that results of the Phase 2 study of the company's lead product candidate, RBX2660 (microbiota suspension) will be presented in two posters and a podium presentation during the IDWeek 2014 conference in Philadelphia from October 8-12. PUNCH CD study results will be presented during the poster...

2014-09-17 04:21:26

GLASGOW, Scotland, September 17, 2014 /PRNewswire/ -- First antibacterial with a new mode of action from a truly novel class of anti-infective in over a decade MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has secured GBP4.0m ($6.4m) to advance the development of its lead antibacterial, MGB-BP-3, against a range of Gram-positive infections including Clostridium...

2014-09-10 16:25:54

DALLAS, September 10, 2014 /PRNewswire/ -- According to the new market research report "Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food, Medical Food, Other Supplements, Device, Drug) - Global Forecast to 2023", published by MarketsandMarkets, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current...

2014-09-08 16:25:18

Phase I/II study also demonstrated SER-109 restoration of a diverse, healthy microbiome CAMBRIDGE, Mass., Sept. 8, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced final data for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic. SER-109, a mixture of bacterial spores, is designed for the treatment of recurrent...

2014-09-07 08:20:25

ROCKVILLE, Md., Sept. 7, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today preclinical data that further validate the Company's novel approach to preventing Clostridium difficile (C. difficile). The U.S. Centers for Disease Control has identified C. difficile as an "urgent public health threat," and it...

rhesus monkey breast or bottle
2014-09-05 02:00:42

Andy Fell, University of California - Davis Health System Infants receiving different diets after birth develop distinct immune systems Infant rhesus monkeys receiving different diets early in life develop distinct immune systems that persist months after weaning, a study by researchers from UC Davis, the California National Primate Research Center (CNPRC) at UC Davis and UC San Francisco has shown. The study, which compares breast- and bottle-fed infants, appears online September 3 in...

Research Sniffs Out Smell Of Disease In Feces
2014-09-02 03:10:38

University of Leicester A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria C. diff, that causes diarrhea, temperature and stomach cramps, has been developed by a team at the University of Leicester. Using a mass spectrometer, the research team has demonstrated that it is possible to identify the unique 'smell' of C. diff which would lead to rapid diagnosis of the condition. What is more, the Leicester team say it could be possible to identify different...

2014-09-02 08:31:00

New TriActive Biotics(TM) Supplement Innovates 3-Stage Delivery For Wellness and Health Market Using Healthy Bacteria PHOENIX, Sept. 2, 2014 /PRNewswire-iReach/ -- This August marks the dawn of a new day for countless Americans suffering from gastrointestinal distress, as a first-of-its-kind innovation is about to change the lives of millions across the U.S. Photo - http://photos.prnewswire.com/prnh/20140829/141661 TriActive Biotics(TM) has solved the longstanding problems with...

2014-09-02 08:29:18

-- Company Completes Final Preclinical Toxicology Study and Prepares to File Investigational New Drug (IND) in 2H 2014 -- ROCKVILLE, Md., Sept. 2, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004. Per U.S. Food and Drug Administration (FDA)...

2014-08-28 08:27:37

-- Fujifilm's pAVEway(TM) Platform Demonstrated >25-fold Improvement in SYN-004 Expression Titers -- ROCKVILLE, Md., Aug. 28, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation of exceptional results from the initial phase of cGMP manufacturing of...


Latest Gut flora Reference Libraries

Large Intestine
2013-04-30 14:11:04

The large intestine is the organ that follows the small intestine but is the last part of the digestive tract before the waste leaves the body. Formation and Orientation The small intestine is on average about five feet long. It is composed of four distinct structural parts; the cecum, colon, and anus. The cecum is the part of the large intestine that comes first. It is separated into three parts. The taeniae coli are three bands of smooth muscle. The haustra are bulges caused by...

72_04c5b3879bb85672771defa94bb4ac91
2011-04-15 14:54:29

Escherichia coli is a Gram-negative rod-shaped bacterium that is commonly found in the lower intestine of warm-blooded organisms. Most strains are harmless; however, some such as O157:H7 can cause food poisoning in humans and are often responsible for product recalls. The normal flora of the gut normally contains the harmless strains and often provide K2 to the body. They are not always confined to the intestine and have the ability to survive briefly outside of the body. It grows easily...

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (3 articles) »
Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'